Document is current
Any future updates will be listed below
-
Authors
Hollak, Carla E. M. https://orcid.org/0000-0003-0464-1078
Sirrs, Sandra
van den Berg, Sibren
van der Wel, Vincent
Langeveld, Mirjam
Dekker, Hanka
Lachmann, Robin
de Visser, Saco J.
- License Information
-
More Information
Article History
Received: 16 June 2020
Accepted: 24 August 2020
First Online: 3 September 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: CH receives payments from the National Healthcare Institute (The Netherlands) as member of the “Horizonscan” for new drugs for metabolic and endocrine disorders and the Dutch Advisory Committee to the insured Package (ACP). She is an unpaid member of Takeda’s Humanitarian Aid Program.CH and ML are involved in pre-marketing studies with orphan drugs for which the Amsterdam University Medical Center receives financial compensation for study costs from Sanofi, Protalix and Idorsia.SS participated in research projects funded by Sanofi, Takeda, Idorsia, Actelion, and Amicus and received support for travel to attend educational meetings from Amicus and Sanofi. She participated in an advisory board for Amicus. The Adult Metabolic Diseases Clinic at Vancouver General Hospital receives unrestricted grant funding from Sanofi, Takeda, and Amicus to support the services of a genetic counselor for patients of the clinic. She is an unpaid member of the multidiscliplinary committee that provides input to our provincial ministry of health on the use of drugs for rare diseases.VvdW is director and shareholder of the company “Patient One”, which develops and orphan drug according to Fair Medicine principles. He is employed by the Fair Medicine Foundation, that is financed by the Dutch government to develop novel pharmaceutical business models.HD receives payments from the National Healthcare Institute as member of the “Horizonscan” for new drugs for metabolic and endocrine disorders. VKS has received financial compensation for work on patient friendly texts from Lysogene and Chiesi. She receives travel support but no fees for patient advisory boards of Sanofi, Takeda, Ultragenyx and Orchard Therapies.RL has received consulting fees from Sanofi/Genzyme, Biomarin and Kyowa Kirin International and honoraria and travel support from Sanofi/Genzyme and Takeda His department receives staff funding from Kyowa Kirin International and research grants from Nutricia. He is unpaid Chair of the Scientific Committee of the Recordati Rare Diseases Foundation.SvdB and SdV declare no conflicts of interest.
